These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 3375501)

  • 1. Interspecific scaling of toxicity data.
    Travis CC; White RK
    Risk Anal; 1988 Mar; 8(1):119-25. PubMed ID: 3375501
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interspecies extrapolation: a reexamination of acute toxicity data.
    Watanabe K; Bois FY; Zeise L
    Risk Anal; 1992 Jun; 12(2):301-10. PubMed ID: 1502377
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interspecies scaling of maximum tolerated dose of anticancer drugs: relevance to starting dose for phase I clinical trials.
    Mahmood I
    Am J Ther; 2001; 8(2):109-16. PubMed ID: 11304664
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serial allometric factor extrapolation: compartmental and physiological pharmacokinetic approaches.
    Hill TA; Wands RC
    Health Phys; 1989; 57 Suppl 1():395-401. PubMed ID: 2514157
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Problems in extrapolating toxicity data for laboratory animals to man.
    Dixon RL
    Environ Health Perspect; 1976 Feb; 13():43-50. PubMed ID: 817897
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetic and toxicity scaling of the antitumor agents amsacrine and CI-921, a new analogue, in mice, rats, rabbits, dogs, and humans.
    Paxton JW; Kim SN; Whitfield LR
    Cancer Res; 1990 May; 50(9):2692-7. PubMed ID: 2328494
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Allometric principles for interspecies extrapolation in toxicological risk assessment--empirical investigations.
    Schneider K; Oltmanns J; Hassauer M
    Regul Toxicol Pharmacol; 2004 Jun; 39(3):334-47. PubMed ID: 15135212
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interspecies extrapolation in risk analysis.
    Travis CC
    Ann Ist Super Sanita; 1991; 27(4):581-93. PubMed ID: 1820730
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Toxicity of dolastatin 10 in mice, rats and dogs and its clinical relevance.
    Mirsalis JC; Schindler-Horvat J; Hill JR; Tomaszewski JE; Donohue SJ; Tyson CA
    Cancer Chemother Pharmacol; 1999; 44(5):395-402. PubMed ID: 10501913
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An FDA oncology analysis of antibody-drug conjugates.
    Saber H; Leighton JK
    Regul Toxicol Pharmacol; 2015 Apr; 71(3):444-52. PubMed ID: 25661711
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Extrapolation of Oligonucleotide Dose Levels Used in Nonclinical Toxicity Studies to Selection of Safe Starting Dose Levels in Human Clinical Trials.
    Kornbrust D
    Nucleic Acid Ther; 2019 Jun; 29(3):123-125. PubMed ID: 30817231
    [TBL] [Abstract][Full Text] [Related]  

  • 12. On the use of scaling factors to improve interspecies extrapolation of acute toxicity in birds.
    Mineau P; Collins BT; Baril A
    Regul Toxicol Pharmacol; 1996 Aug; 24(1 Pt 1):24-9. PubMed ID: 8921543
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of rodent-only toxicology for early clinical trials with novel cancer therapeutics.
    Newell DR; Burtles SS; Fox BW; Jodrell DI; Connors TA
    Br J Cancer; 1999 Nov; 81(5):760-8. PubMed ID: 10555743
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interspecies scaling: predicting clearance of anticancer drugs in humans. A comparative study of three different approaches using body weight or body surface area.
    Mahmood I
    Eur J Drug Metab Pharmacokinet; 1996; 21(3):275-8. PubMed ID: 8980928
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Toxicological evaluation of 1,2-bis(methylsulfonyl)-1-(2-chloroethyl)-2-(methylaminocarbonyl)hydrazine (VNP40101M), a novel alkylating agent with potential antitumor activity, with intravenous administration in rats and dogs.
    Lee KC; Almassian B; Noveroske J
    Int J Toxicol; 2002; 21(1):23-38. PubMed ID: 11936896
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Basis for body weight exponent (0.75) as a scaling factor in energy metabolism and risk assessment.
    Sidhu KS
    J Appl Toxicol; 1992 Oct; 12(5):309-10. PubMed ID: 1447474
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Review of interspecies risk comparisons.
    Brown SL; Brett SM; Gough M; Rodricks JV; Tardiff RG; Turnbull D
    Regul Toxicol Pharmacol; 1988 Jun; 8(2):191-206. PubMed ID: 3051142
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Benefits of the maximum tolerated dose (MTD) and maximum tolerated concentration (MTC) concept in aquatic toxicology.
    Hutchinson TH; Bögi C; Winter MJ; Owens JW
    Aquat Toxicol; 2009 Feb; 91(3):197-202. PubMed ID: 19124163
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Application of preclinical data to initiate the modified continual reassessment method for maximum tolerated dose-finding trials.
    Mahmood I
    J Clin Pharmacol; 2001 Jan; 41(1):19-24. PubMed ID: 11144990
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lognormal distributions for skin area as a function of body weight.
    Burmaster DE
    Risk Anal; 1998 Feb; 18(1):27-32. PubMed ID: 9523442
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.